Satsuma Pharmaceuticals, Inc.
(NASDAQ : STSA)

( )
STSA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
1.75%131.320.7%$869.57m
PFEPfizer Inc.
0.92%36.120.9%$677.48m
MRKMerck & Co., Inc.
0.33%84.590.7%$653.74m
ABBVAbbVie, Inc.
0.29%73.592.3%$567.84m
BMYBristol-Myers Squibb Company
1.64%51.611.4%$507.77m
LLYEli Lilly and Company
1.32%108.331.0%$317.22m
NVSNovartis AG Sponsored ADR
-1.17%85.600.2%$154.25m
AZNAstraZeneca PLC Sponsored ADR
1.03%44.031.2%$153.02m
GSKGlaxoSmithKline plc Sponsored ADR
-0.14%42.190.3%$93.41m
SNYSanofi Sponsored ADR
-0.31%44.810.2%$82.63m
NVONovo Nordisk A/S Sponsored ADR Class B
1.84%52.170.1%$75.52m
LCILannett Company, Inc.
-0.18%11.0735.6%$19.29m
AKTXAkari Therapeutics Plc Sponsored ADR
-0.55%1.821.6%$0.76m
EPIXESSA Pharma Inc
6.20%3.300.1%$0.08m

Company Profile

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.